This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Pilaralisib
- DrugBank Accession Number
- DB11772
- Background
Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and Breast Cancer, among others.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Pilaralisib (DB11772)
- Weight
- Average: 541.02
Monoisotopic: 540.1346522 - Chemical Formula
- C25H25ClN6O4S
- Synonyms
- Pilaralisib
- External IDs
- SAR-245408
- SAR245408
- XL-147
- XL147
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
In preclinical studies, Pilaralisib slowed tumor growth or caused tumor shrinkage in multiple preclinical cancer models, including breast, lung, ovarian, and prostate cancers, and gliomas. Pilaralisib has also been shown to enhance the anti- tumor effects of several chemotherapeutic agents and an inhibitor of epidermal growth factor receptor (EGFR) in preclinical cancer models.
- Mechanism of action
Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Activation of PI3K is a frequent event in human tumors, promoting tumor cell growth, survival, and resistance to chemotherapy and radiotherapy. Inactivation of PI3K has been shown to inhibit growth and induce apoptosis (programmed cell death) in tumor cells.
Target Actions Organism UPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Not Available Humans - Absorption
Orally available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Alpha amino acid amides
- Alternative Parents
- Benzenesulfonamides / Quinoxalines / Benzenesulfonyl compounds / Anilides / Methoxyanilines / Phenoxy compounds / Anisoles / Methoxybenzenes / N-arylamides / Alkyl aryl ethers show 14 more
- Substituents
- Alkyl aryl ether / Alpha-amino acid amide / Amine / Aminopyrazine / Aminosulfonyl compound / Anilide / Aniline or substituted anilines / Anisole / Aromatic heteropolycyclic compound / Aryl chloride show 37 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 60ES45KTMK
- CAS number
- 934526-89-3
- InChI Key
- QINPEPAQOBZPOF-UHFFFAOYSA-N
- InChI
- InChI=1S/C25H25ClN6O4S/c1-25(2,27)24(33)28-15-7-6-8-17(13-15)37(34,35)32-23-22(29-19-9-4-5-10-20(19)30-23)31-21-14-16(36-3)11-12-18(21)26/h4-14H,27H2,1-3H3,(H,28,33)(H,29,31)(H,30,32)
- IUPAC Name
- 2-amino-N-[3-({3-[(2-chloro-5-methoxyphenyl)amino]quinoxalin-2-yl}sulfamoyl)phenyl]-2-methylpropanamide
- SMILES
- COC1=CC=C(Cl)C(NC2=C(NS(=O)(=O)C3=CC(NC(=O)C(C)(C)N)=CC=C3)N=C3C=CC=CC3=N2)=C1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 56599306
- PubChem Substance
- 347828124
- ChemSpider
- 29340997
- BindingDB
- 50197062
- ChEMBL
- CHEMBL3360203
- ZINC
- ZINC000100472223
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Endometrial Cancer / Neoplasms, Endometrial 1 1 Completed Not Available Solid Tumors 1 1 Completed Treatment Astrocytoma, Grade IV / High Grade Glioma: Glioblastoma (GBM) 1 1 Completed Treatment Cancer (Solid Tumors) 1 1 Completed Treatment Cancer / Endometrial Carcinoma / Non-Small Cell Lung Cancer (NSCLC) / Ovarian Carcinoma 1 1 Completed Treatment Cancer / Lymphoma 1 1 Completed Treatment Cancer / Non-Small Cell Lung Cancer (NSCLC) 1 1 Completed Treatment Malignant Neoplasm 2 1 Withdrawn Treatment Breast Cancer / Cancer / Non-Small Cell Lung Cancer (NSCLC) 1 1, 2 Completed Treatment Breast Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0048 mg/mL ALOGPS logP 3.98 ALOGPS logP 3.27 Chemaxon logS -5 ALOGPS pKa (Strongest Acidic) 5.99 Chemaxon pKa (Strongest Basic) 8.48 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 148.33 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 142.09 m3·mol-1 Chemaxon Polarizability 52.89 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Protein serine/threonine kinase activity
- Specific Function
- Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns (Phosphatidylinositol), PtdIns4P (Phosphatidylinositol 4-phosphate) and PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate...
- Gene Name
- PIK3CA
- Uniprot ID
- P42336
- Uniprot Name
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
- Molecular Weight
- 124283.025 Da
Drug created at October 20, 2016 20:46 / Updated at February 21, 2021 18:53